Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from DVAX

Trump Advises Parents To Split Vaccines, Delay Hepatitis B Shots Until Age 12: 'This Is Based On What I Feel'

President Donald Trump on Monday offered advice on childhood vaccination schedules, encouraging parents to split up certain immunizations and delay certain others, in sharp contradiction to current medical recommendations.

Dynavax Says Investigational Shingles Vaccine At Par With GSK's Vaccine In Early-Stage Study

Dynavax Says Investigational Shingles Vaccine At Par With GSK's Vaccine In Early-Stage Study

Dynavax Technologies Corporation (NASDAQ:DVAX) announced topline results from Part 1 of its randomized, observer-blinded, and active-controlled Phase 1/2 clinical trial of Z-1018, a shingles vaccine candidate, head-to-head versus Shingrix in participants aged 50 to 69 years on Thursday.

3 Biotech Stocks Paving the Way for Bullish Investment Gains

3 Biotech Stocks Paving the Way for Bullish Investment Gains

The biotech industry is rapidly expanding due to the popularity of personalized medicines and novel therapies, government initiatives, and technological adoption. Hence, quality biotech stocks Alnylam Pharmaceuticals (ALNY), Dynavax Technologies (DVAX), and Innoviva (INVA) could pave the way for substantial gains. Read more….

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

3 Biotech Buys Under $15

Amid technological advancements, growing needs for personalized medicines, and government initiatives, the biotech market is poised to thrive in the foreseeable future. Given this backdrop, it could be wise to buy biotech stocks Dynavax Technologies Corporation (DVAX), Entrada Therapeutics (TRDA), and Shionogi & Co., Ltd. (SGIOY), trading under $15 now.…

Dynavax's Adjuvant-Based Bivalent COVID-19 Vaccine Candidate Shows Encouraging Preclinical Action

Clover Biopharmaceuticals Ltd announced new promising data from a preclinical study on its bivalent vaccine candidate, which combines the trimeric spike antigens from the original SARS-CoV-2 strain and the omicron variant. Clover developed the SCB-2019 antigen, a stabilized trimeric form of the S-protein based on the original strain of the SARS-CoV-2 virus. It…

Dynavax Adjuvanted Clover Bio's COVID-19 Vaccine Booster Shows Durable Protection Against Omicron

Clover Biopharmaceuticals Ltd's follow-up analysis for efficacy in the SPECTRA Phase 2/3 trial of SCB-2019 COVID-19 vaccine provided high and durable protection in individuals five months after the second dose. The follow-up analysis involved 26,400 individuals. Against any variant, efficacy was maintained at 100% against severe COVID-19 and 95% against COVID-19 associated…

Dynavax Technologies Earnings Perspective: Return On Capital Employed

According to Benzinga Pro, during Q4, Dynavax Technologies (NASDAQ:DVAX) earned $99.78 million, a 450.96% increase from the preceding quarter. Dynavax Technologies also posted a total of $195.07 million in sales, a 80.17% increase since Q3.

inkl

Read news from The Economist, FT, and more,
with one subscription

Recap: Dynavax Technologies Q4 Earnings

Recap: Dynavax Technologies Q4 Earnings

Dynavax Technologies (NASDAQ:DVAX) reported its Q4 earnings results on Monday, February 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

People

163,569 stories

Neha PanjwaniFrom

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

334,341 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play